Friday, February 27, 2026

1089 Inc. Partners with Price Forbes and Oka-Lloyd's Syndicate 1922 to Launch Market-Defining First: Carbon Asset Insurance Framework for Transportation and Energy Sectors

 LONDON & BOULDER, Colo. - Friday, 27. February 2026



New program introduces dedicated insurance safeguards and immutable transfer infrastructure to advance fiscal maturation of global carbon markets, enabling scaled participation across world's highest-emitting sectors, Transportation and Energy.


 


(BUSINESS WIRE)--1089 Inc., in collaboration with Price Forbes and Oka, The Carbon Insurance Company, announce launch of an insured carbon asset designed to bring institutional safeguards, disciplined financial architecture, and verifiable data integrity to carbon markets.


The framework provides defined risk coverage for 1089’s CX89 Advanced Fuels Carbon Assets, underwritten by Lloyd’s Syndicate 1922 and placed with the support of Price Forbes and Oka. The program introduces institutional-grade protection designed to prevent performance losses resulting from credit degradation between wrapping and minting.


Luke Hanley, Founder and CEO of 1089 Inc., shared the framework’s core thesis:


“The future of carbon markets is not built on environmental penance. It is built on structured participation that aligns financial incentives with decarbonization outcomes."


Founder and CEO of Oka, Chris Slater, added, “Voluntary carbon markets have previously lacked the financial infrastructure required for institutional capital. By embedding defined invalidation risk coverage directly into the asset, we introduce certainty and balance sheet strength where it matters most. This represents a decisive step toward establishing carbon as an investable, insurable asset class.”


The framework integrates embedded insurance, registry oversight, and immutable accounting. Enabling organizations to address fuels-linked operational emissions across supply-chains and convert market demand into financial incentives supporting scaled low-emission fuel production.


"Given the complexity of global carbon markets, it's more practical to bring finance to carbon than the inverse," Hanley states.


Spenser Lee, Chief Brokering Officer of Price Forbes, emphasized the significance, “By securing Lloyd’s capacity for embedded invalidation coverage, we’ve created transparent risk-transfer framework enhancing liquidity and investor confidence. This is the kind of disciplined brokering approach that will be required as carbon markets mature.”


CX89 Advanced Fuels Carbon Assets address Scope 1-3 emissions across Oil & Gas, Data Centers, Manufacturing, EV-charging, Power Generation, and Distribution across Aviation, Automotive, Maritime, and Rail.


CX89 Advanced Fuels Carbon Assets are available for global purchase.


Organizations and institutions seeking fuel-linked offset assets or portfolio diversification, as well as media representatives, may direct enquiries to 1089 at info@1089inc.com


1089 Inc. is a carbon asset infrastructure company pioneering the evolution of global carbon markets.


www.1089inc.com


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20260226012782/en/



Permalink

https://www.aetoswire.com/en/news/2702202653570


Contacts

Rhiannon O'Donnell

info@1089inc.com


 

New Lenovo Service Delivers Always-On Infrastructure: Premier Support Plus for Servers Powered by Proactive, AI-Driven Support

 (BUSINESS WIRE)--Lenovo today announced the availability of Lenovo Premier Support Plus for Servers, a new premium support offering designed to help enterprises reduce downtime, simplify IT operations, and keep mission-critical infrastructure always ready. Built for today’s always-on environments, Premier Support Plus combines AI-driven proactive and predictive support, preventative maintenance, 24/7 access to Lenovo experts, and designated Service Engagement Managers to help organizations move from reactive issue resolution to proactive system care.


As digital operations continue to expand and infrastructure environments grow more complex, IT teams are under increasing pressure to maintain uptime while managing limited resources. Traditional, reactive support models can lead to extended outages, repeated issues, and unpredictable costs. Lenovo Premier Support Plus for Servers addresses these challenges by identifying potential issues early and resolving them before they impact business operations.


“With Premier Support Plus for Servers, Lenovo is helping customers stay ahead of potential infrastructure issues before they affect the business,” said John Stamer, Vice President & GM, Global Product & Sustainability Services at Lenovo. “By combining predictive intelligence, expert oversight, and rapid response, we’re enabling organizations to protect uptime, reduce risk, and focus on innovation.”


Premier Support Plus for Servers is Lenovo’s highest-tier support offering for enterprise server environments, building on the foundation of Lenovo Premier Support. The service is designed for Lenovo ThinkSystem and ThinkAgile servers and delivers intelligent support for organizations that depend on continuous availability. Key capabilities of Lenovo Premier Support Plus for Servers include:


Proactive and predictive support powered by AI-driven monitoring and Call Home automation, which detects potential issues early and automatically initiates support cases and parts dispatch.

Preventative maintenance through wellness dashboards, firmware health checks, and expert guidance to improve system health, reliability, and longevity.

24/7 expert assistance with a 4-hour onsite response objective for critical issues, helping ensure faster recovery and minimal disruption.

A designated Lenovo Service Engagement Manager who provides onboarding, ongoing reporting, and regular service reviews, serving as a single point of accountability.

Keep Your Drive, enabling customers to retain failed drives to maintain control of sensitive data and meet internal security and compliance requirements.

Global service coverage across more than 75 markets, delivering consistent, enterprise-grade support worldwide.

“According to recent IDC research, customers are placing as much, if not more, emphasis on services capabilities as on product features when evaluating vendors,” says Rob Brothers, VP, Services, IDC. “It’s not just the product, but the experience surrounding it that helps customers choose the right vendor for their needs. With the addition of Premier Support Plus, Lenovo is expanding its services portfolio, which is designed to enhance the overall Lenovo server experience.”


For customers with mission-critical environments where downtime is not an option, Lenovo also offers Committed Service Repair as an optional add-on. This enhanced service provides a 6-hour onsite repair commitment, delivering faster resolution for the most demanding operational needs.


Premier Support Plus combines predictive detection, preventative maintenance, and guided planning to keep infrastructure optimized and ready to scale. With designated account oversight from a Lenovo Service Engagement Manager, global coverage, and data retention controls through Keep Your Drive, customers gain consistent, transparent support they can trust. By shifting the burden of monitoring, maintenance, and escalation to Lenovo, IT teams can spend less time reacting to issues and more time driving strategic initiatives.


Premier Support Plus for Servers is part of Lenovo’s broader services portfolio, which includes Lenovo Lifecycle Services which are designed to help customers plan, deploy, manage, optimize and evolve IT infrastructure with confidence.


To learn more about Lenovo Premier Support Plus for Servers, visit: https://www.lenovo.com/us/en/services/support-services/premier-support-plus-for-infrastructure/.


About Lenovo


Lenovo is a US$69 billion revenue global technology powerhouse, ranked #196 in the Fortune Global 500, and serving millions of customers every day in 180 markets. Focused on a bold vision to deliver Smarter Technology for All, Lenovo has built on its success as the world’s largest PC company with a full-stack portfolio of AI-enabled, AI-ready, and AI-optimized devices (PCs, workstations, smartphones, tablets), infrastructure (server, storage, edge, high performance computing and software defined infrastructure), software, solutions, and services. Lenovo’s continued investment in world-changing innovation is building a more equitable, trustworthy, and smarter future for everyone, everywhere. Lenovo is listed on the Hong Kong stock exchange under Lenovo Group Limited (HKSE: 992) (ADR: LNVGY). To find out more visit https://www.lenovo.com, and read about the latest news via our StoryHub.


Disclaimers


Committed Service Repair (CSR) service availability may vary by product and location. Refer to the Lenovo Locator Tool to see if CSR is available in your location.


Response time is a target, not a guaranteed commitment. For more information, see the Lenovo Data Center Services Agreement.


LENOVO, THINKSYSTEM and THINKAGILE are trademarks of Lenovo. All other trademarks are the property of their respective owners. ©2026 Lenovo Group Limited. All rights reserved.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20260226453532/en/



Permalink

https://aetoswire.com/en/news/54433834


Contacts

 

Zeno Group for Lenovo SSG

Email: LenovoSSG@zenogroup.com

BeOne Medicines Announces Fourth Quarter and Full Year 2025 Financial Results, Highlighting Global Success of BRUKINSA and Foundational Oncology Leadership

 Total global revenues of $1.5 billion and $5.3 billion for the fourth quarter and full year, increases of 33% and 40% from the prior-year periods

Global BRUKINSA (zanubrutinib) revenues of $1.1 billion and $3.9 billion for the fourth quarter and full year, increases of 38% and 49% from the prior-year periods

Diluted GAAP Earnings per American Depository Share (ADS) of $0.58 and $2.53 for the fourth quarter and full year; non-GAAP diluted Earnings per ADS of $1.95 and $8.09 for the fourth quarter and full year

Full year 2026 total revenue guidance of $6.2 billion to $6.4 billion

(BUSINESS WIRE)--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced financial results and corporate updates from the fourth quarter and full year 2025.


“These strong financial results for the fourth quarter and full year 2025 underscore our continued evolution as a global oncology leader with durable competitive advantages in clinical development and manufacturing and one of the industry’s deepest and most differentiated pipelines,” said John V. Oyler, Co-Founder, Chairman and CEO at BeOne. “BRUKINSA has firmly established itself as the global leader in the BTK inhibitor class, distinguished by broad regulatory approvals, expanding geographic reach, strong physician adoption, and unmatched long-term efficacy and safety data in CLL. At the same time, we are securing new indications and expanded reimbursement for TEVIMBRA across key markets worldwide. With our late-stage, foundational hematology assets nearing commercialization and a robust solid tumor portfolio delivering encouraging data, we are well positioned to extend our leadership and drive the next phase of sustainable global growth.”


(Amounts in thousands of U.S. dollars full year GAAP amounts audited, all other amounts unaudited)



*  For an explanation of our use of non-GAAP financial measures refer to the “Note Regarding Use of Non-GAAP Financial Measures” section later in this press release and for a reconciliation of each non-GAAP financial measure to the most comparable GAAP measures, see the table at the end of this press release.


Fourth Quarter and Full Year 2025 Financial Results


Product Revenue, which represents 99% of total revenue, totaled $1.5 billion and $5.3 billion for the fourth quarter and full year of 2025, representing growth of 32% and 40%, compared to the prior-year periods.


BRUKINSA: Global sales totaled $1.1 billion and $3.9 billion the fourth quarter and full year of 2025, representing growth of 38% and 49%, compared to the prior-year periods; U.S. sales of BRUKINSA totaled $845 million and $2.8 billion in the fourth quarter and full year of 2025, representing growth of 37% and 45%, compared to the prior-year periods.

TEVIMBRA (tislelizumab): Global sales totaled $182 million and $737 million, in the fourth quarter and full year of 2025, representing growth of 18% and 19%, compared to the prior-year periods.

Amgen in-licensed products: Global sales totaled $112 million and $486 million for the fourth quarter and full year of 2025, representing growth of 11% and 33%, compared to prior-year periods.

Gross Margin as a percentage of global product sales for the fourth quarter and full year of 2025 was 90.4% and 87.3%, compared to 85.6% and 84.3%, in the prior-year periods on a GAAP basis. On an adjusted basis, which does not include depreciation and amortization, gross margin as a percentage of global product sales increased to 90.7% and 87.8% for the fourth quarter and full year of 2025, compared to 87.4% and 85.5%, in the prior-year periods.


Operating Expenses


The following table summarizes operating expenses for the fourth quarter of 2025 and 2024:


Research and Development (R&D) Expenses increased for the fourth quarter and full year of 2025 compared to the prior-year periods on both a GAAP and adjusted basis. Upfront fees and milestone payments related to in-process R&D for in-licensed assets totaled nil and $0.7 million in the fourth quarter and full year of 2025, compared to $63 million and $114 million in the prior-year periods.


Selling, General and Administrative (SG&A) Expenses increased for the fourth quarter and full year of 2025 compared to the prior-year periods on both a GAAP and adjusted basis. SG&A expenses as a percentage of product sales were 38% and 39% for the fourth quarter and full year of 2025, compared to 45% and 48% in the prior-year periods.


Net Income/(Loss) and Basic/Diluted Earnings Per Share


GAAP net income for the fourth quarter and full year of 2025 was $67 million and $287 million, an increase of $218 million and $932 million, over the prior-year periods, primarily attributable to revenue growth and improved operating leverage. Included within GAAP net income for full year 2025 were $76 million of equity investment impairment charges, $25 million of non-recurring tax expenses and $20 million of timing related tax expenses in certain jurisdictions, which were primarily incurred in the fourth quarter.


For the fourth quarter of 2025, basic and diluted earnings per share were $0.05 and $0.04 per share and $0.60 and $0.58 per American Depositary Share (ADS), compared to basic loss of $0.11 per share and $1.43 per ADS in the prior-year period. For the full year of 2025, basic and diluted earnings per share were $0.20 and $0.19 per share and $2.63 and $2.53 per ADS, compared to basic loss of $0.47 per share and $6.12 per ADS in the prior-year period.


Free Cash Flow for the fourth quarter of 2025 was $380 million, representing an increase of $397 million over the prior-year period. For the full year of 2025, free cash flow was $942 million, representing an increase of $1.6 billion over the prior-year period.


For further details on BeOne’s 2025 Financial Statements, please see BeOne’s Annual Report on Form 10-K for fiscal year 2025 filed with the U.S. Securities and Exchange Commission.


Full Year 2026 Guidance


BeOne’s financial guidance is summarized below:


BeOne’s total revenue guidance for full year 2026 of $6.2 billion to $6.4 billion includes expectations for strong revenue growth driven by BRUKINSA’s U.S. leadership position and continued global expansion in both Europe and other important rest of world markets. Gross margin percentage is expected to be in the high-80% range and includes the impact of product mix and a full year of 2026 productivity improvements. Guidance for combined operating expenses on a GAAP basis includes expectations of investment to support growth in both commercial and research at a pace that continues to deliver meaningful operating leverage.


The Company is providing the following additional guidance on items impacting net income and earnings per ADS:


Other income (expense): estimated range of $25 million to $50 million in expense, includes interest amortization from Royalty Pharma arrangement.

Income tax outlook: earnings may provide sufficient positive evidence to reverse certain valuation allowances in 2026, resulting in a material tax benefit when recognized; the timing and magnitude of a potential reversal is uncertain; prior to reversal, income tax expense should trend with earnings per historical relationship.

Diluted ADS outstanding: the Company expects diluted ADSs outstanding of approximately 118 million.

Fourth Quarter Business Highlights


Core Marketed Products


BRUKINSA (zanubrutinib)


Presented 6-year landmark results from the Phase 3 SEQUOIA trial and long-term results from the Phase 3 ALPINE trial at the American Society of Hematology (ASH) Annual Meeting, confirming sustained benefit for the treatment of adult patients with treatment-naïve (TN) and relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), respectively.

Sonrotoclax (BCL2 inhibitor)


Received first global approvals in China for the treatment of adult patients with:

R/R mantle cell lymphoma (MCL) who have received at least two systemic therapies, including a Bruton tyrosine kinase (BTK) inhibitor;

and R/R CLL/SLL who have previously received at least one systemic therapy, including a BTK inhibitor.

Granted U.S. Food and Drug Administration (FDA) priority review for the treatment of adult patients with R/R MCL.

Submitted Marketing Authorization Application in the European Union for the treatment of adult patients with R/R MCL.

Enrolled first subject in Phase 3 trial in combination with BRUKINSA as a fixed-duration regimen versus acalabrutinib plus venetoclax for the treatment of adult patients with TN CLL.

TEVIMBRA (tislelizumab)


Presented full results in partnership with Jazz Pharmaceuticals and Zymeworks from the HERIZON-GEA-01 trial in combination with ZIIHERA (zanidatamab) and chemotherapy, demonstrating statistically significant and clinically meaningful improvement in overall survival versus trastuzumab plus chemotherapy for the first-line treatment of adult patients with HER2-positive gastroesophageal adenocarcinoma (GEA).

Select Clinical-Stage Programs


Hematology


BGB-16673 (BTK chimeric degradation activation compound (CDAC)): Presented results at ASH from the Phase 1 CaDAnCe-101 trial for the treatment of adult patients with R/R CLL.

Breast and Gynecologic Cancers


BG-75202 (KAT6A/B inhibitor): Initiated first in human study.

BG-75908 (CDK2 CDAC): Initiated first in human study.

Lung Cancer


BG-C0902 (EGFRxMETxMET antibody-drug conjugate): Initiated first in human study.

Gastrointestinal Cancers


BGB-B2033 (GPC3x41BB bispecific antibody): Granted FDA Fast Track Designation for the treatment of adult patients with hepatocellular carcinoma who experience disease progression on or after post-systemic therapy.

Anticipated R&D Milestones


The Company’s earnings conference call for the fourth quarter and full year 2025 will be broadcast via webcast at 8:00 a.m. ET on Thursday, February 26, 2026, and will be accessible through the Investors section of BeOne’s website at www.beonemedicines.com. Supplemental information in the form of a slide presentation, transcript of prepared remarks, and a replay of the webcast will also be available.


About BeOne


BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The Company has a growing global team spanning six continents who are driven by scientific excellence and exceptional speed to reach more patients than ever before.


To learn more about BeOne, please visit www.beonemedicines.com and follow us on LinkedIn, X, Facebook and Instagram.


Forward-Looking Statements


This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding: potential commercialization of BeOne’s late-stage hematology assets; BeOne’s next phase of global growth; BeOne’s future revenue, gross margin percentage, operating expenses, operating income, other income or expense, income tax and diluted ADS outstanding; BeOne’s expectations regarding continued global expansion and investment to support growth; upcoming R&D milestones to be achieved by BeOne; the timing of clinical developments and data readouts; and BeOne’s plans, commitments, aspirations and goals under the caption “About BeOne.” Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeOne’s ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; BeOne’s ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeOne’s ability to obtain and maintain protection of intellectual property for its medicines and technology; BeOne’s reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeOne’s limited experience in obtaining regulatory approvals and commercializing pharmaceutical products; BeOne’s ability to obtain additional funding for operations and to complete the development of its drug candidates and achieve and maintain profitability; and those risks more fully discussed in the section entitled “Risk Factors” in BeOne’s most recent periodic report filed with the U.S. Securities and Exchange Commission (“SEC”), as well as discussions of potential risks, uncertainties, and other important factors in BeOne’s subsequent filings with the SEC. All information in this press release is as of the date of this press release, and BeOne undertakes no duty to update such information unless required by law. BeOne’s financial guidance is based on estimates and assumptions that are subject to significant uncertainties.


View source version on businesswire.com: https://www.businesswire.com/news/home/20260226660598/en/



Permalink

https://www.aetoswire.com/en/news/54433496


Contacts

 Investor Contact

Liza Heapes

+1 857-302-5663

ir@beonemed.com


Media Contact

Kyle Blankenship

+1 667-351-5176

media@beonemed.com


 

Galderma’s Nemluvio® (nemolizumab) Demonstrates Long-Term Disease Control in Prurigo Nodularis up to Three Years

  • Results from an interim analysis of the OLYMPIA long-term extension (LTE) study show that Nemluvio maintained long-term disease control up to three years, with clinically meaningful improvements in itch intensity, skin lesions and quality of life1
  • These results, to be presented at 2026 Winter Clinical™ Miami, mark the longest LTE study in prurigo nodularis reported to date1
  • Nemluvio is the first approved monoclonal antibody that specifically targets and inhibits the signaling of IL-31 – a neuroimmune cytokine that drives itch and other symptoms in prurigo nodularis2-5
  • Nemluvio is approved by multiple regulatory authorities around the world for the treatment of prurigo nodularis and moderate-to-severe atopic dermatitis, including in the United States (U.S.) and European Union (EU)4,5

 

(BUSINESS WIRE)--Galderma (SIX: GALD) today announced new data from the OLYMPIA open-label extension study investigating the long-term safety and efficacy of Nemluvio in moderate-to-severe prurigo nodularis.1 Results showed that Nemluvio maintained long-term disease control and a well-tolerated safety profile, with clinically meaningful improvements in itch intensity, skin lesions and quality of life up to three years.1 Results will be presented at 2026 Winter Clinical Miami and build on previous data from OLYMPIA – the largest completed pivotal clinical program in prurigo nodularis and the only one with a LTE study.1,6,7


This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260226796734/en/


 


“Prurigo nodularis is not only intensely itchy, painful and uncomfortable, it can also take a profound toll on sleep, emotional wellbeing, and daily functioning. That’s why achieving sustained, long-term disease control is critical for patients. These data show that Nemluvio can make a meaningful difference to people’s lives by improving itch, skin lesions and quality of life up to three years, with a well-tolerated safety profile.”


 


DOCTOR SHAWN KWATRA, M.D.


LEAD INVESTIGATOR OF OLYMPIA PROGRAM


JOSEPH W. BURNETT ENDOWED PROFESSOR AND CHAIRMAN OF DERMATOLOGY UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE


 


Nemluvio demonstrated long-term improvements in itch intensity, skin lesions and quality of life

The OLYMPIA LTE study was designed to assess the safety and efficacy of Nemluvio in patients with prurigo nodularis up to four years and included 508 patients from the phase II trial and the OLYMPIA 1 and 2 phase III trials.1 At Week 148, in evaluable patients, the interim analysis showed that Nemluvio maintained long-term disease control with a consistent safety profile:


Over 70% of patients achieved clear or almost clear skin lesions based on Investigator’s Global Assessment score, and over 85% achieved more than 75% of healed lesions based on prurigo activity score.1

Over 85% of patients achieved a clinically meaningful itch improvement, and about three-quarters attained an itch-free or nearly itch-free state.1

About 90% of patients achieved a clinically meaningful improvement in quality of life, and >50% achieved a Dermatology Life Quality Index score of zero or one, meaning no effect of the disease on quality of life.1

The long-term safety profile of Nemluvio remained consistent with previous findings and aligned with previously established safety data for prurigo nodularis.1

 


“We recognize that prurigo nodularis is a chronic, debilitating condition that patients often struggle with for many years. Our goal has always been to generate robust, long-term evidence on how to ease such disease burden for patients suffering from prurigo nodularis, drawing on data from the largest completed pivotal clinical program and now the longest extension study reported in this disease to date.”


 


BALDO SCASSELLATI SFORZOLINI, M.D., PH.D.


GLOBAL HEAD OF R&D


GALDERMA


 


Nemluvio is the first approved monoclonal antibody that specifically targets IL-31 receptor alpha, inhibiting the signaling of IL-31.2-5 IL-31 is a neuroimmune cytokine that drives itch and other symptoms in prurigo nodularis.2-5 Nemluvio is approved by multiple regulatory authorities around the world for the treatment of prurigo nodularis and moderate-to-severe atopic dermatitis, including in the U.S. and EU.4,5


Media can find more information and resources on prurigo nodularis in this toolkit.


About Nemluvio

Nemluvio was initially developed by Chugai Pharmaceutical Co., Ltd. In 2016, Galderma obtained exclusive rights to the development and marketing of nemolizumab worldwide, except in Japan. In Japan, nemolizumab is marketed as Mitchga® and is approved for the treatment of prurigo nodularis, as well as pruritus associated with atopic dermatitis in pediatric, adolescent, and adult patients.8,9


Nemluvio was approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with prurigo nodularis, and patients 12 years and older with moderate-to-severe atopic dermatitis, in combination with topical corticosteroids and/or calcineurin inhibitors when the disease is not adequately controlled with topical prescription therapies.4 To date, Nemluvio is approved for both moderate-to-severe atopic dermatitis and prurigo nodularis by multiple regulatory authorities around the world, including in the EU, Australia, Singapore, Switzerland and the United Kingdom. Additional regulatory submissions and reviews are ongoing.


About prurigo nodularis

Prurigo nodularis is a chronic, debilitating, and distinct neuroimmune skin disease characterized by the presence of intense itch and thick skin nodules covering large body areas.10-12 It is estimated to affect between 7-111 people per 100,000 in the EU depending on the country and up to 181,000 people in the U.S.13-16 The majority of patients report that the persistent itch negatively impacts their quality of life.17 Furthermore, the intense itch associated with prurigo nodularis results in significant sleep disturbance and further contributes to reduced quality of life.18,19


About Galderma

Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.


References


Kwatra SG, et al. Nemolizumab long-term safety and efficacy up to 148 weeks in the OLYMPIA open-label extension study in patients with prurigo nodularis. Presented at Winter Clinical Miami; February 27- March 1, 2026; Florida, U.S.

Silverberg JI, et al. Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus. J Allergy Clin Immunol. 2020;145(1):173-182. doi: 10.1016/j.jaci.2019.08.013.

Bewley A, et al. Prurigo Nodularis: A Review of IL-31RA Blockade and Other Potential Treatments. Dermatol Ther (Heidelb). 2022;12(9):2039-2048. doi: 10.1007/s13555-022-00782-2.

Nemluvio® U.S. Prescribing Information. Available online. Accessed February 2026.

Nemluvio® European Medicines Agency. Summary of Product Characteristics. Available online. Accessed February 2026.

ClinicalTrials.Gov. A Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN) (NCT04501679). Available online. Accessed February 2026.

ClinicalTrials.Gov. Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN) (NCT04501666). Available online. Accessed February 2026.

Chugai Pharmaceutical Co., Ltd. Maruho Obtained Regulatory Approval for Mitchga, the first Antibody Targeting IL-31 for Itching Associated with Atopic Dermatitis. Available online. Accessed February 2026.

Chugai Pharmaceutical Co., Ltd. Mitchga Approved for Itching in Pediatric Atopic Dermatitis and Prurigo Nodularis, for its Subcutaneous Injection 30mg Vials. Available online. Accessed February 2026.

Ständer S, et al. IFSI-guideline on chronic prurigo including prurigo nodularis. Itch. 2020;5(4):e42. doi: 10.1097/itx.0000000000000042.

Huang AH, et al. Prurigo nodularis: Epidemiology and clinical features. J Am Acad Dermatol. 2020;83(6):1559-1565. doi: 10.1016/j.jaad.2020.04.183.

Pereira MP, et al. European academy of dermatology and venereology European prurigo project: expert consensus on the definition, classification and terminology of chronic prurigo. J Eur Acad Dermatol Venereol. 2018;32(7):1059-1065. doi: 10.1111/jdv.14570.

Ryczek A, and Reich A. Prevalence of Prurigo Nodularis in Poland. Acta Derm Venereol. 2020;100:adv00155. doi: 10.2340/00015555-3518.

Ständer S, et al. Epidemiology of Prurigo Nodularis compared with Psoriasis in Germany: A Claims Database Analysis. Acta Derm Venereol. 2020;100(18):1-6. doi: 10.2340/00015555-3655.

Kwatra SG, et al. Prevalence of prurigo nodularis in the United States. JAAD Int. 2024;18:134-136. doi: 10.1016/j.jdin.2023.12.013.

Ständer S, et al. Prevalence of prurigo nodularis in the United States of America: A retrospective database analysis. JAAD Int. 2020;2:28-30. doi: 10.1016/j.jdin.2020.10.009.

Todberg T, et al. Treatment and Burden of Disease in a Cohort of Patients with Prurigo Nodularis: A Survey-based Study. Acta Derm Venereol. 2020;100(8):adv00119. doi: 10.2340/00015555-3471.

Kwatra SG. Breaking the Itch–Scratch Cycle in Prurigo Nodularis. N Engl J Med. 2020;382(8):757-758. doi: 10.1056/NEJMe1916733.

Aggarwal P, et al. Clinical characteristics and disease burden in prurigo nodularis. Clin Exp Dermatol. 2021;46(7):1277-1284. doi: 10.1111/ced.14722.

 


View source version on businesswire.com: https://www.businesswire.com/news/home/20260226796734/en/



Permalink

https://www.aetoswire.com/en/news/2702202653573


Contacts

For further information:


Christian Marcoux, M.Sc.

Chief Communications Officer

christian.marcoux@galderma.com

+41 76 315 26 50


Richard Harbinson

Corporate Communications Director

richard.harbinson@galderma.com

+41 76 210 60 62


Céline Buguet

Franchises and R&D Communications Director

celine.buguet@galderma.com

+41 76 249 90 87


Emil Ivanov

Head of Strategy, Investor Relations, and ESG

emil.ivanov@galderma.com

+41 21 642 78 12


Jessica Cohen

Investor Relations and Strategy Director

jessica.cohen@galderma.com

+41 21 642 76 43


 

Allianz Achieves Record Operating Profit of 17.4 Billion Euros – Excellent Start to New Strategic Cycle


 MUNICH -

Excellent momentum and record operating profit


Total business volume rises 8.11 percent and reaches 186.9 billion euros with contributions from all segments

Operating profit increases 8.4 percent to 17.4 billion euros, our highest operating profit ever

Shareholders’ core net income advances 10.9 percent to 11.1 billion euros

Core earnings per share (EPS) grow 12.5 percent and reach 28.61 euros

Core return on equity (RoE) reaches an excellent level of 18.1 percent

Solvency II ratio2 increases 10 percentage points to 218 percent supported by excellent capital generation

4Q 2025


Diversified growth and double-digit increase in shareholders’ core net income

Total business volume rises 6.5 1 percent with contributions from all segments

Operating profit increases 3.0 percent to 4.3 billion euros, driven by excellent contribution from the Property-Casualty segment

Shareholders’ core net income advances 12.2 percent and reaches 2.7 billion euros

Outlook & other


For 2026, Allianz targets an operating profit of 17.4 billion euros, plus or minus 1 billion euros3

Management to propose a dividend per share of 17.10 euros, an increase of 11.0 percent from 2024

Allianz has announced a new share buy-back program of up to 2.5 billion euros on February 25, 2026

CEO comment


“Allianz’s record results for 2025 demonstrate – again – our ability to deliver reliably, including in rapidly shifting and increasingly divisive environments. The strength of our performance and fundamentals goes well beyond our financial discipline and operational resilience. Our success is also powered by our leading brand strength, record customer loyalty, and highly motivated employees.


Customers expect protection and peace of mind at a price that they can afford, which is why our ability to offer superior value is so vital to the continued growth of our customer base. To mitigate deepening polarization in the world, it remains our strategic priority – as well as our societal responsibility – to ensure that people can access the freedom and security that our products and services provide.”


- Oliver Bäte, Chief Executive Officer of Allianz SE


FINANCIAL HIGHLIGHTS


Allianz Group: An excellent start to our Capital Markets Day delivery


Key performance indicator


 

4Q 2025


 


 

Change vs

prior year


 

12M 2025


 


 

Change vs

prior year


 

Total business volume (€ bn)4


 

45.7


 

6.5


%


 

186.9


 

8.1


%


Operating profit (€ mn)


 

4,297


 


 

3.0


%


 

17,374


 


 

8.4


%


Shareholders’ core net income (€ mn)


 

2,731


 


 

12.2


%


 

11,113


 


 

10.9


%


Core return on equity (%)


 

18.1


 


 

1.2%-p


 

Solvency II ratio (%)


 

218


 


 

10%-p


 

CFO comment


“We had an excellent start into our new strategic cycle. Our performance highlights the strength and resilience of Allianz’s business model.


Allianz’s record results for 2025 are characterized by very good growth across our segments and excellent profitability, while we further enhanced our financial strength. This demonstrates our ability to create sustainable value for our customers and shareholders alike.


As we pursue our 2026 target of an operating profit of 17.4 billion euros, plus or minus 1 billion euros, we continue the focused execution of our strategic Capital Markets Day priorities to deliver on our 2025 – 2027 plan.”


- Claire-Marie Coste-Lepoutre, Chief Financial Officer of Allianz SE


Allianz’s 12M 2025 results were excellent. Allianz sustained its momentum across all three segments and achieved a record operating profit.


Our total business volume expanded to 186.9 billion euros (12M 2024: 179.8 billion euros). Internal growth, which excludes the effects of foreign-currency translation as well as acquisitions and divestments, was strong at 8.1 percent, supported by growth across all segments.


Operating profit reached a record level of 17.4 (16.0) billion euros, an increase of 8.4 percent. The Property-Casualty business was the main growth driver and all business segments exceeded their full-year outlook midpoints.


Shareholders’ core net income rose by 10.9 percent to 11.1 (10.0) billion euros. Adjusted for a one-off tax provision related to the sale of our stake in our Indian Joint Ventures in 1Q 2025 and the divestment gain on the UniCredit Joint Venture in 2Q 2025, shareholders’ core net income was up by 9.3 percent.


Core earnings per share (EPS)5 amounted to 28.61 (25.42) euros, an increase of 12.5 percent. Adjusted for the above-mentioned one-off tax provision and divestment gain, core earnings per share rose 10.8 percent.


Allianz has delivered an excellent core return on equity (RoE)5 of 18.1 percent in 12M 2025 (12M 2024: 16.9 percent). Adjusted for the effects of the one-off tax provision and divestment gain, the core return on equity was 17.8 percent.


This performance was achieved while Allianz further strengthened its capitalization. The Solvency II ratio was 218 percent, an increase of 10 percentage points compared to full-year 2024 (209 percent) and 3Q 2025 (209 percent). This development was supported by excellent operating capital generation of 25 percentage points after tax/before dividend.


In 4Q 2025, Allianz delivered a strong performance, characterized by good growth across our three segments and excellent profitability.


Our total business volume amounted to 45.7 billion euros (4Q 2024: 45.9 billion euros). Internal growth was good at 6.5 percent and all segments contributed.


Operating profit rose 3.0 percent to 4.3 (4.2) billion euros, reaching 27 percent of our full-year outlook midpoint. The increase was mainly driven by excellent operating profit growth in our Property-Casualty business.


Shareholders’ core net income advanced 12.2 percent to 2.7 (2.4) billion euros. A higher operating profit and an improved non-operating result contributed.


Outlook


In 2026, Allianz targets an operating profit of 17.4 billion euros, plus or minus 1 billion euros.


Other


The Board of Management proposes a dividend per share of 17.10 euros (2024: 15.40 euros) for 2025, an increase of 11.0 percent from 2024.


On February 25, 2026, Allianz has announced a new share buy-back program of up to 2.5 billion euros.


Property-Casualty insurance: Excellent delivery across all dimensions


Key performance indicator


 

4Q 2025


 


 

Change vs

prior year


 

12M 2025


 


 

Change vs

prior year


 

Total business volume (€ bn)4


 

19.9


 

6.7


%


 

86.7


 

8.2


%


Operating profit (€ mn)


 

2,134


 


 

9.6


%


 

8,992


 


 

13.9


%


Combined ratio (%)


 

93.6


 


 

-1.1%-p


 

92.2


 


 

-1.3%-p


 

Loss ratio (%)


 

69.8


 


 

-0.9%-p


 

68.3


 


 

-1.0%-p


 

Expense ratio (%)


 

23.8


 


 

-0.2%-p


 

23.9


 


 

-0.3%-p


 

Core messages Property-Casualty insurance 12M 2025


Very good internal growth across retail and commercial

Record operating profit, well exceeding the full-year outlook midpoint

Excellent combined ratio supported by underwriting actions

In the 12M 2025 period, total business volume rose to 86.7 billion euros (12M 2024: 82.9 billion euros). Internal growth was very good at 8.2 percent.


Operating profit was excellent at 9.0 (7.9) billion euros, well exceeding our full-year outlook midpoint of 8.0 billion euros. Operating profit growth of 13.9 percent was almost exclusively driven by a higher operating insurance service result.


The combined ratio was at an excellent level of 92.2 percent (93.4 percent), with improvements in the loss ratio and the expense ratio. The loss ratio reached 68.3 percent, an improvement of 1.0 percentage point compared to prior year (69.3 percent). Lower natural catastrophe losses and underlying improvements from underwriting actions overcompensated a conservative run-off ratio. The expense ratio improved by 0.3 percentage points to 23.9 percent (24.2 percent), reflecting a successful ongoing productivity focus.


The retail6 business delivered excellent internal growth of 9 percent while our commercial7 business grew by 7 percent.


Profitability in both retail and commercial was strong. The retail combined ratio improved 1.8 percentage points to 92.4 percent (94.1 percent), while in commercial the combined ratio reached an excellent level of 91.7 percent (92.2 percent), an improvement of 0.5 percentage points.


Core messages Property-Casualty insurance 4Q 2025


Strong internal growth of 6.7 percent

Excellent operating profit of 2.1 billion euros, up 10 percent

Very good combined ratio, supported by a better loss ratio and expense ratio

In 4Q 2025, total business volume reached 19.9 billion euros (4Q 2024: 19.5 billion euros), a strong internal growth of 6.7 percent.


The operating profit grew to 2.1 (1.9) billion euros, an increase of 9.6 percent, reaching 27 percent of our full-year outlook midpoint. A stronger operating insurance service result was the main driver.


The combined ratio improved to a very good level of 93.6 percent (94.7 percent). The loss ratio was 69.8 percent (70.7 percent), an improvement of 0.9 percentage points. The expense ratio improved by 0.2 percentage points to 23.8 percent (24.1 percent).


Our retail business delivered excellent internal growth of 9 percent and the combined ratio reached 94.5 percent (94.0 percent).


The commercial business achieved an internal growth of 3 percent, carefully managing the market environment, while the combined ratio improved by 4.0 percentage points to a strong level of 92.6 percent (96.6 percent).


Life/Health insurance: Consistently good results


Key performance indicator


 

4Q 2025


 


 

Change vs

prior year


 

12M 2025


 


 

Change vs

prior year


 

PVNBP (€ mn)


 

21,163


 

-0.2


%


 

84,682


 

3.5


%


New business margin (%)


 

5.8


 


 

0.3%-p


 

5.7


 


 

-0.0%-p


 

Value of new business (€ mn)


 

1,217


 


 

5.3


%


 

4,829


 


 

2.9


%


Operating profit (€ mn)


 


1,364


 


 


-4.2


%


 


5,601


 


 


1.7


%


Contractual Service Margin (€ bn, eop)


 


55.7


 


 


1.4%8


 

 


55.7


 


 


5.2%9


 

Core messages Life/Health insurance 12M 2025


Good PVNBP growth of 3.5 percent from exceptionally high prior year level

Very good normalized CSM growth of 5.2 percent

Operating profit above full-year outlook midpoint

In 12M 2025, PVNBP, the present value of new business premiums, reached 84.7 billion euros (12M 2024: 81.8 billion euros), an increase of 3.5 percent from an exceptionally high prior year level or 7.5 percent higher adjusted for foreign currency translation effects and scope changes10. Growth was spread across most regions. The share of new business premiums generated in our preferred lines was 91 percent (93 percent).


The new business margin remained strong at 5.7 percent (5.7 percent) and the value of new business rose to 4.8 (4.7) billion euros, an increase of 5.8 percent adjusted for foreign currency translation effects and scope changes10.


Operating profit grew to 5.6 (5.5) billion euros, an increase of 1.7 percent, and exceeding our full-year outlook midpoint.


The Contractual Service Margin (CSM) remained broadly stable at 55.7 billion euros compared to 55.6 billion euros11 at the end of 2024. Very good normalized CSM growth of 5.2 percent was largely offset by foreign currency translation effects and non-economic movements.


Core messages Life/Health insurance 4Q 2025


New business margin strong at 5.8 percent

Value of new business increases 12 percent adjusted for foreign currency translation effects and scope changes

Operating profit good at 1.4 billion euros

In 4Q 2025, PVNBP, the present value of new business premiums, amounted to 21.2 billion euros (4Q 2024: 21.2 billion euros), an increase of 7.8 percent adjusted for foreign currency translation effects and scope changes10. The share of new business premiums generated in our preferred lines was 90 percent (92 percent).


The new business margin (NBM) of 5.8 percent (5.5 percent) was strong and above our ambition of at least 5 percent. The value of new business (VNB) increased by 5.3 percent to 1.2 (1.2) billion euros or 11.7 percent adjusted for foreign currency translation effects and scope changes10.


Operating profit reached a good level of 1.4 (1.4) billion euros, amounting to 25 percent of our full-year outlook midpoint.


Contractual Service Margin (CSM) increased to 55.7 billion euros (3Q 2025: 55.5 billion euros). Normalized CSM growth of 1.4 percent was very good and overcompensated non-economic movements.


Asset Management: Excellent third-party net inflows


Key performance indicator


 

4Q 2025


 


 

Change vs

prior year


 

12M 2025


 


 

Change vs

prior year


 

Operating revenues (€ bn)12


 

2.3


 

5.8


%


 

8.5


 

5.9


%


Operating profit (€ mn)


 

928


 


 

-1.5


%


 

3,345


 


 

3.3


%


Cost-income ratio (%)


 

60.0


 


 

-0.0%-p


 

60.7


 


 

-0.4%-p


 

Third-party net flows (€ bn)


 

45.5


 


 

173.2


%


 

139.3


 


 

64.2


%


Third-party assets under management (€ bn)


 

1,990


 


 

3.6


%


Average third-party assets under management (€ bn)


 


1,978


 


 


4.8


%


 


1,914


 


 


5.8


%


Core messages Asset Management 12M 2025


Operating profit increases 3 percent to 3.3 billion euros

Cost-income ratio improves to 60.7 percent, ahead of full-year ambition of around 61 percent

Excellent third-party net inflows of 139 billion euros

In 12M 2025, operating revenues increased to 8.5 billion euros (12M 2024: 8.3 billion euros), an internal growth of 5.9 percent. Growth was driven by higher AuM-driven revenues, which advanced by 8.3 percent adjusted for foreign currency translation effects. This was supported by higher average third-party AuM.


Operating profit rose to 3.3 (3.2) billion euros, up 3.3 percent, or 6.9 percent adjusted for foreign currency translation effects. The cost-income ratio (CIR) improved to a very good level of 60.7 percent (61.1 percent), ahead of our full-year ambition of around 61 percent. This development reflects strong underlying revenue momentum and management actions.


Third-party assets under management amounted to 1.990 (1.920) trillion euros as of December 31, 2025, reaching an all-time high. Excellent net inflows of 139 billion euros and positive market effects of 94 billion euros were partly offset by negative foreign currency translation effects of 170 billion euros. Average third-party assets under management amounted to 1.914 trillion euros, 5.8 percent above the 2024 average.


Core messages Asset Management 4Q 2025


Assets under management (AuM)-driven revenues grow by 10 percent (F/X adjusted)

Operating profit at 928 million euros, reaching 28 percent of our full-year outlook midpoint

Strong third-party net inflows of 45 billion euros

In 4Q 2025, operating revenues reached 2.3 billion euros (4Q 2024: 2.4 billion euros), an internal growth of 5.8 percent. This was due to higher AuM-driven revenues, which increased by 10.5 percent adjusted for foreign currency translation effects.


Operating profit amounted to 928 (941) million euros, an increase of 5.3 percent adjusted for foreign currency translation effects. The cost-income ratio (CIR) was stable at an excellent level of 60.0 percent (60.0 percent).


Third-party assets under management of 1.990 trillion euros as of December 31, 2025 increased by 3.2 percent compared to 3Q 2025 (4Q 2024: 1.920 trillion euros; 3Q 2025: 1.928 trillion euros). Strong net inflows of 45 billion euros and market effects of 20 billion euros were the drivers. Average third-party assets under management increased 4.8 percent compared to 4Q 2024 and reached 1.978 trillion euros.


FOOTNOTES


_____________________________________

1


Internal growth; total growth 4.0 percent in 12M 2025 and -0.5 percent in 4Q 2025.


2


Solvency II ratio / Solvency II capitalization ratio: ratio that expresses the capital adequacy of a company by comparing own funds to SCR. This applies to all information related to the Solvency II ratio in this document.


3


As always, natural catastrophes and adverse developments in the capital markets, as well as factors stated in our cautionary note regarding forward-looking statements may severely affect the operating profit and/or net income of our operations and the results of the Allianz Group.


4


Change refers to internal growth.


5


Core EPS and core RoE calculation based on shareholders‘ core net income.


6


Retail including SME and Fleet. This applies to all information related to retail in this document.


7


Commercial including large Corporate, MidCorp, credit insurance, internal and 3rd party R/I. This applies to all information related to commercial in this document.


8


Normalized CSM growth fourth quarter 2025.


9


Normalized CSM growth 2025, percentage calculated including the scope changes in the base value in the first quarter 2025 and including UniCredit Allianz Vita S.p.A. until the sale in the second quarter 2025.


10


Sale of our stake in UniCredit JV and transfer of our German accident insurance with premium refund (APR) and the Austrian health businesses from the P/C segment to the L/H segment.


11


Figure includes gross CSM of EUR 0.8 bn as of December 31, 2024 for UniCredit Allianz Vita S.p.A., which was classified as held for sale in the third quarter of 2024.


12


Internal growth.


   

4Q & 12M 2025 RESULTS TABLE


Allianz Group - key figures 4th quarter and fiscal year 2025


 

 


 

 


 

 


 

 


 


 

 


 

 


 

 


 


 


 


 


 

 


 


4Q 2025


 


4Q 2024


 


Delta


 


 


12M 2025


 


12M 2024


 


Delta


 


Total business volume


 

€ bn


 


45.7


 


45.9


 


-0.5%


 


 


186.9


 


179.8


 


4.0%


 


- Property-Casualty


 


 


 

€ bn


 


19.9


 


19.5


 


1.7%


 


 


86.7


 


82.9


 


4.7%


 


- Life/Health


 


 


 

€ bn


 


23.6


 


24.3


 


-2.6%


 


 


92.3


 


89.3


 


3.4%


 


- Asset Management


 


 

€ bn


 


2.3


 


2.4


 


-1.5%


 


 


8.5


 


8.3


 


2.2%


 


- Consolidation


 


 

€ bn


 


-0.1


 


-0.3


 


-42.7%


 


 


-0.6


 


-0.7


 


-16.5%


 


Operating profit / loss


 

 


 

€ mn


 


4,297


 


4,174


 


3.0%


 


 


17,374


 


16,023


 


8.4%


 


- Property-Casualty


 


 


 

€ mn


 


2,134


 


1,948


 


9.6%


 


 


8,992


 


7,898


 


13.9%


 


- Life/Health


 


 


 

€ mn


 


1,364


 


1,424


 


-4.2%


 


 


5,601


 


5,505


 


1.7%


 


- Asset Management


 


 


 

€ mn


 


928


 


941


 


-1.5%


 


 


3,345


 


3,239


 


3.3%


 


- Corporate and Other


 


 


 

€ mn


 


-129


 


-140


 


-7.7%


 


 


-565


 


-615


 


-8.2%


 


- Consolidation


 

€ mn


 


0


 


1


 


-69.6%


 


 


1


 


-4


 


n.m.


 


Net income


 


 


 

€ mn


 


2,821


 


2,636


 


7.0%


 


 


11,430


 


10,540


 


8.4%


 


- attributable to non-controlling interests


 

€ mn


 


157


 


163


 


-3.9%


 


 


655


 


609


 


7.7%


 


- attributable to shareholders


 


 

€ mn


 


2,664


 


2,472


 


7.7%


 


 


10,775


 


9,931


 


8.5%


 


Shareholders’ core net income1


 

€ mn


 


2,731


 


2,434


 


12.2%


 


 


11,113


 


10,017


 


10.9%


 


Core earnings per share2


 


 


7.17


 


6.31


 


13.7%


 


 


28.61


 


25.42


 


12.5%


 


Dividend per share


 


 



 



 



 


 


17.10


3


15.40


 


11.0%


 


Additional KPIs


 


 

 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


- Group


 


Core return on equity4


 

%


 



 



 



 


 


18.1%


 


16.9%


 


1.2%


-p


- Property-Casualty


 


Combined ratio


 

%


 


93.6%


 


94.7%


 


-1.1%


-p


 


92.2%


 


93.4%


 


-1.3%


-p


- Life/Health


 


New business margin


 

%


 


5.8%


 


5.5%


 


0.3%


-p


5.7%


 


5.7%


 


-0.0%


-p


- Asset Management


 


Cost-income ratio


 

%


 


60.0%


 


60.0%


 


-0.0%


-p


 


60.7%


 


61.1%


 


-0.4%


-p


 


 


 


 

 


 


 


 


 


 


 


 


 


12/31/2025


 


12/31/2024


 


Delta


 


Shareholders' equity5


 


 


 

€ bn


 


 


 


 


 


 


 


 


62.7


 


60.3


 


4.0%


 


Contractual service margin (net)6


 

€ bn


 


 


 


 


 


 


 


 


35.4


 


34.5


 


2.4%


 


Solvency II capitalization ratio7


 

%


 


 


 


 


 


 


 


 


218%


 


209%


 


10%


-p


Third-party assets under management


 


 

€ bn


 


 


 


 


 


 


 


 


1,990


 


1,920


 


3.6%


 


 

 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 


 

Please note: The figures are presented in millions of Euros, unless otherwise stated. Due to rounding, numbers presented may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures.


1_


Presents the portion of shareholders’ net income before non-operating market movements and before amortization of intangible assets from business combinations (including any related income tax effects).


2_


Calculated by dividing the respective period’s shareholders' core net income, adjusted for net financial charges related to undated subordinated bonds classified as shareholders' equity, by the weighted average number of shares outstanding (basic core EPS).


3_


Proposal.


4_


Represents the ratio of shareholders’ core net income to the average shareholders’ equity at the beginning and at the end of the year. Shareholders’ core net income is adjusted for net financial charges related to undated subordinated bonds classified as shareholders’ equity. From the average shareholders’ equity, undated subordinated bonds classified as shareholders’ equity, unrealized gains and losses from insurance contracts and other unrealized gains and losses are excluded.


5_


Excluding non-controlling interests.


6_


Includes net CSM of EUR 0.3bn as of 31 December 2024 for UniCredit Allianz Vita S.p.A., which was classified as held for sale in 3Q 2024. Sale has been completed in 2Q 2025.


7_


Risk capital figures are group diversified at 99.5% confidence level.


RATING


Ratings1


 

S&P Global


 

Moody’s


 

A.M. Best2


Insurer financial strength rating


 

AA | stable outlook


 

Aa2 | stable outlook


 

A+ | stable outlook


Counterparty credit rating


 

AA | stable outlook


 

Not rated


 

aa3 | stable


Senior unsecured debt rating


 

AA


 

Aa2 | stable outlook


 

aa | stable


Subordinated debt rating


 

A+/A


 

A1/A34 | stable outlook


 

aa- / a+ | stable


Commercial paper (short term) rating


 

A-1+


 

Prime-1


 

Not rated


1


Includes ratings for securities issued by Allianz Finance II B.V. and Allianz Finance Corporation.


2


A.M. Best's Rating Reports reproduced on www.allianz.com appear under licence from A.M. Best Company and do not constitute, either expressly or implicitly, an endorsement of Allianz's products or services. A.M. Best's Rating Reports are the copyright of A.M. Best Company and may not be reproduced or distributed without the express written consent of A.M. Best Company. Visitors to www.allianz.com are authorised to print a single copy of the rating report displayed there for their own use. Any other printing, copying or distribution is strictly prohibited. A.M. Best's ratings are under continual review and subject to change or affirmation. To confirm the current rating visit www.ambest.com.


3


Issuer credit rating.


4


Final ratings vary on the basis of the terms.


 

 


Related links


Media Conference

February 26, 2026, 11:00 AM CET: YouTube (English language)


Analyst Conference

February 26, 2026, 2:00 PM CET: YouTube (English language)


Results

The results and related documents can be found in the download center.


Upcoming events


Annual Report

March 13, 2026


Annual General Meeting

May 7, 2026


Financial Results 1Q 2026

May 13, 2026


More information can be found in the financial calendar.


About Allianz


The Allianz Group is one of the world’s leading insurers and asset managers with around 97 million customers* in nearly 70 countries. Allianz customers benefit from a broad range of personal and corporate insurance services, ranging from property, life and health insurance to assistance services to credit insurance and global business insurance. Allianz is one of the world’s largest investors, managing around 764 billion euros** on behalf of its insurance customers. Furthermore, our asset managers PIMCO and Allianz Global Investors manage about 2.0 trillion euros** of third-party assets. Thanks to our systematic integration of ecological and social criteria in our business processes and investment decisions, we are among the leaders in the insurance industry in the Dow Jones Sustainability Index. In 2025, over 156,000 employees achieved total business volume of 186.9 billion euros and an operating profit of 17.4 billion euros for the Group.


*Customer count reflects Allianz customers in consolidated entities that are part of the customer reporting scope only.


** As of December 31, 2025.


These assessments are, as always, subject to the disclaimer provided below.


Cautionary note regarding forward-looking statements


This document includes forward-looking statements, such as prospects or expectations, that are based on management's current views and assumptions and subject to known and unknown risks and uncertainties. Actual results, performance figures, or events may differ significantly from those expressed or implied in such forward-looking statements.


Deviations may arise due to changes in factors including, but not limited to, the following: (i) the general economic and competitive situation in the Allianz’s core business and core markets, (ii) the performance of financial markets (in particular market volatility, liquidity, and credit events), (iii) adverse publicity, regulatory actions or litigation with respect to the Allianz Group, other well-known companies and the financial services industry generally, (iv) the frequency and severity of insured loss events, including those resulting from natural catastrophes, and the development of loss expenses, (v) mortality and morbidity levels and trends, (vi) persistency levels, (vii) the extent of credit defaults, (viii) interest rate levels, (ix) currency exchange rates, most notably the EUR/USD exchange rate, (x) changes in laws and regulations, including tax regulations, (xi) the impact of acquisitions including and related integration issues and reorganization measures, and (xii) the general competitive conditions that, in each individual case, apply at a local, regional, national, and/or global level. Many of these changes can be exacerbated by terrorist activities.


No duty to update


Allianz assumes no obligation to update any information or forward-looking statement contained herein, save for any information we are required to disclose by law.


Other


The figures regarding the net assets, financial position and results of operations have been prepared in conformity with International Financial Reporting Standards. Information is based on preliminary figures. Final results for fiscal year 2025 will be released on March 13, 2026 (publication of the Annual Report). This is a translation of the German Quarterly and Full Year Earnings Release of the Allianz Group. In case of any divergences, the German original is binding.


Privacy Note


Allianz SE is committed to protecting your personal data. Find out more in our privacy statement.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20260225107874/en/



Permalink

https://aetoswire.com/en/news/2602202653553


Contacts

Media contacts

Frank Stoffel Tel. +49 160 9011 5157 e-mail: frank.stoffel@allianz.com

Ann-Kristin Manno Tel. +49 151 2990 1517 e-mail: ann-kristin.manno@allianz.com

Johanna Oltmann Tel. +49 151 1164 6551 e-mail: johanna.oltmann@allianz.com

Fabrizio Tolotti Tel. +49 151 5995 6396 e-mail: fabrizio.tolotti@allianz.com


Investor Relations contacts

Andrew Ritchie Tel. +49 89 3800 3963 e-mail: andrew.ritchie@allianz.com

Reinhard Lahusen Tel. +49 89 3800 17224 e-mail: reinhard.lahusen@allianz.com

Christian Lamprecht Tel. +49 89 3800 3892 e-mail: christian.lamprecht@allianz.com

Tobias Rupp Tel. +49 89 3800 7151 e-mail: tobias.rupp@allianz.com


 

Venture Global Announces New Long-Term LNG Partnership with Hanwha of Korea

ARLINGTON, Va. - Friday, 27. February 2026


20-year sales and purchase agreement marks Venture Global’s first SPA with a Korean entity


 


(BUSINESS WIRE)--Today, Venture Global, Inc. (NYSE: VG) and Hanwha Aerospace Co., Ltd. announced the execution of a new Sales and Purchase Agreement (SPA) for the purchase of 1.5 million tonnes per annum (MTPA) of U.S. liquefied natural gas (LNG) from Venture Global for twenty years starting in 2030. This agreement brings Venture Global’s long-term contracted portfolio to over 46 MTPA.


“Venture Global is thrilled to announce our first long-term supply deal in Korea through a new partnership with Hanwha Aerospace which marks another important step in expanding reliable, long-term LNG supply to our partners in Asia,” said Mike Sabel, CEO of Venture Global. “We are proud to support growing global energy needs with low-cost, secure American LNG while strengthening the strategic energy partnership between the United States and South Korea to support long-term industrial and economic growth.”


About Venture Global


Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (LNG) with over 100 MTPA of capacity in production, construction, or development. Venture Global began producing LNG from its first facility in 2022 and is now one of the largest LNG exporters in the United States. The company’s vertically integrated business includes assets across the LNG supply chain including LNG production, natural gas transport, shipping and regasification. The company’s first three projects, Calcasieu Pass, Plaquemines LNG, and CP2 LNG, are located in Louisiana along the Gulf of America. Venture Global is developing Carbon Capture and Sequestration projects at each of its LNG facilities.


About Hanwha Aerospace


Hanwha Aerospace is a core affiliate of the Hanwha Group, operating as a global company primarily focused on aerospace and defense, with expanding operations into energy and industrial infrastructure. Hanwha Aerospace is building an LNG value chain in collaboration with other Hanwha Group affiliates to enhance energy security and advance the effectiveness of clean energy solutions globally.


Forward-looking Statements


This press release contains forward-looking statements. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements, other than statements of historical facts, included herein are “forward-looking statements.” In some cases, forward-looking statements can be identified by terminology such as “may,” “might,” “will,” “could,” “should,” “expect,” “plan,” “project,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “pursue,” “target,” “continue,” the negative of such terms or other comparable terminology.


These forward-looking statements, which are subject to risks, uncertainties and assumptions about us, may include statements about our future performance, our contracts, our anticipated growth strategies and anticipated trends impacting our business. These statements are only predictions based on our current expectations and projections about future events. There are important factors that could cause our actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. Those factors include our need for significant additional capital to construct and complete future projects and related assets, and our potential inability to secure such financing on acceptable terms, or at all; our potential inability to accurately estimate costs for our projects, and the risk that the construction and operations of natural gas pipelines and pipeline connections for our projects suffer cost overruns and delays related to obtaining regulatory approvals, development risks, labor costs, unavailability of skilled workers, operational hazards and other risks; the uncertainty regarding the future of global trade dynamics, international trade agreements and the United States’ position on international trade, including the effects of tariffs; our dependence on our EPC and other contractors for the successful completion of our projects, including the potential inability of our contractors to perform their obligations under their contracts; various economic and political factors, including opposition by environmental or other public interest groups, or the lack of local government and community support required for our projects, which could negatively affect the permitting status, timing or overall development, construction and operation of our projects; and risks related to other factors discussed under “Item 1A.—Risk Factors” of our annual report on Form 10-K for the year ended December 31, 2024 as filed with the Securities and Exchange Commission (“SEC”) and any subsequent reports filed with the SEC. Any forward-looking statements contained herein speak only as of the date of this press release and are based on assumptions that we believe to be reasonable as of this date. We undertake no obligation to update these statements to reflect subsequent events or circumstances, except as may be required by law.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20260226064547/en/



Permalink

https://www.aetoswire.com/en/news/2702202653572


Contacts

Investor contact:

Ben Nolan

IR@ventureglobalLNG.com


Media contact:

Shaylyn Hynes

press@ventureglobalLNG.com

Amazfit Introduces the Active 3 Premium: Turning Daily Movement into Meaningful Progress for Entry-Level Runners

  MILPITAS, Calif. - Thursday, 26. February 2026 AETOSWire 



Premium materials, a 12-day battery life and new running features provide support for those kicking off their running journey


 


(BUSINESS WIRE)--Amazfit, a leading global smart wearable brand owned by Zepp Health, today announced the Amazfit Active 3 Premium, a compact, 4-button smartwatch designed as an entry point into structured running and hybrid training. Made for athletes building consistency across different forms of training, the Active 3 Premium supports road running and hybrid routines that combine endurance, strength, and studio-based workouts. Its compact design makes it easy to train across environments, from neighborhood runs to studio floors, offering a capable, approachable experience without feeling overbuilt or intimidating.


Unlike high-performance racing watches that can feel overwhelming, the Active 3 Premium focuses on delivering structured training programs, accurate route navigation, and comprehensive health insights in a refined, durable design that fits seamlessly into everyday life.


“The Active 3 Premium has everything I need to stay on top of my training, but it doesn’t feel intimidating or overbuilt for someone starting their journey,” said Gabby Thomas, 5-time Olympic medalist and Amazfit ambassador. “I believe performance starts with consistency, and this watch makes it easy to stay connected to your body, your workouts, and your recovery without overthinking it.”


Train Smarter, Run Stronger


Active 3 Premium features built-in running workouts and Zepp Coach science-backed adaptive running plans created to guide users through structured effort, helping them avoid burnout while building the consistency needed for their first race. Advanced Running Metrics like posture monitoring, threshold insights, ground contact balance tracking, and rhythm analysis give users deeper visibility into their running form, helping fine-tune performance and reduce injury risk over time.


Own the Route with Advanced GPS Mapping


Supported by a six-satellite positioning system and offline maps, the Active 3 Premium allows for phone-free running with turn-by-turn navigation, automatic rerouting and point-to-point route planning. With 4GB of internal storage, users can keep their favorite podcasts and maps directly on their wrist, ensuring they stay on track without distractions.


Premium Craftsmanship Built for Everyday Performance


Crafted with a 45mm stainless-steel frame and four tactile control buttons, the watch is as durable as it is sleek and comfortable. The 1.32-inch AMOLED display is protected by scratch-resistant Sapphire Glass and features 3,000 nits peak brightness, ensuring that training data is crystal clear even in direct sunlight.


Run Farther and Charge Less


Built to go the distance, the Active 3 Premium provides up to 12 days of battery under typical use and up to 7 days under heavy activity, supporting long workouts, recovery days, and everyday wear without the interruption of frequent charging.


24/7 Health Monitoring and Smart Connectivity


Powered by Amazfit's BioTracker™ technology, the Active 3 Premium provides continuous monitoring of heart rate, blood oxygen, stress levels, sleep quality, and recovery insights, helping users better understand their body and readiness. With a built-in microphone and speaker, users can take Bluetooth calls from the wrist, and with the Zepp Flow™ voice assistant, it's easy to control features with voice commands for all-day connection.


A Robust Ecosystem of Third-Party Training Integrations


To support athletes at every level, Amazfit Active 3 Premium integrates with leading third-party training platforms including TrainingPeaks, Strava, Runna, and Intervals.icu. Through seamless syncing with the Zepp App, users can connect their preferred coaching, planning, and performance-tracking tools, ensuring workouts, training data, and activity insights flow easily between platforms


Availability


The Amazfit Active 3 Premium will be available for purchase in Apex Silver, Atlas Blue, and Aero White starting February 26, 2026, for $169.99 on Amazfit.com and Amazon.


About Amazfit


Amazfit, a global smart wearable and fitness leader is part of Zepp Health (NYSE: ZEPP), a health technology company with its principal office based in Gorinchem, the Netherlands. Zepp Health operates as a distributed organization, with team members and offices across the Americas, Europe, Asia, and other global markets.


Amazfit builds smart wearables designed around movement — training with intention, recovery with balance, and evolution over time. Built for the way people train today, Amazfit blends endurance, strength, and recovery into a single, coherent rhythm to support sustainable progress over time.


Behind Amazfit is Zepp, which builds the intelligence that supports its training experience. For more information, visit www.amazfit.com.


 


View source version on businesswire.com: https://www.businesswire.com/news/home/20260226378156/en/



Permalink

https://www.aetoswire.com/en/news/2602202653561


Contacts

Media Contacts

Max Borges Agency for Amazfit

amazfit@maxborgesagency.com


Mary Thompson Woodbury

Head of PR, Amazfit North America

Mary.woodbury@zepp.com